4 Jan 2017 15:43
4 January 2017
IXICO plc
("IXICO" or the "Company")
Issue of 590,093 Deferred Consideration Shares
IXICO, the brain health company, announces the issue of 590,093 ordinary shares of 1p each as Deferred Consideration in accordance with the terms of the Share Purchase Agreement (the 'Agreement') entered into between the Company and Optimal Medicine Limited on 18 November 2015.
Under the terms of the Agreement, the Deferred Consideration Shares were to be issued on 4 January 2017 following the expiry of the period during which the Company may bring a warranty claim and the determination of the Board of Directors that no such warranty claim is to be made by the Company.
Application has been made for the Deferred Consideration Shares to be admitted to AIM on 9 January 2017. Upon admission of the Deferred Consideration Shares to AIM, the enlarged issued share capital of the Company will be 27,063,284 ordinary shares. The Company does not hold any shares in treasury. Consequently, 27,063,284 is the figure which may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.
For further information please contact:
IXICO plc Derek Hill, Chief Executive Officer Susan Lowther, Chief Financial Officer |
Tel: +44 20 3763 7499 |
| |||
| |||||
Shore Capital (Nomad and Broker) Bidhi Bhoma / Edward Mansfield | Tel: +44 20 7408 4090 |
| |||
| |||||
FTI Consulting Limited (Investor Relations) Simon Conway/Mo Noonan/Matthew Moss | Tel: +44 20 3727 1000 |
| |||
About IXICO
IXICO's innovative and proprietary digital healthcare technologies help those involved in researching and treating serious diseases to capture and analyse clinical data to make rapid, informed decisions. In clinical research this includes the phenotyping of patients, quantification of disease pathology and measurement of patient outcomes. In clinical practice the mobile health and digital decision support technologies aid diagnosis, patient engagement and monitoring. IXICO is also collaborating with partners to develop companion digital health products targeted at improving patient outcomes.
The Company's brain health focus includes Alzheimer's disease, Huntington's disease, multiple sclerosis, Parkinson's disease, behavioural health, child and adolescent mental health.
More information is available on www.ixico.com
Ixico (IXI)